secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2026-04-08T23:59:59+00:00
Accession:  0001493152-26-015602
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce closes $2M preferred stock financing from prior $20M commitment; conversion price $0.55
--------------------------------------------------------------------------------

- Gross proceeds of $2M from second tranche under November 2025 agreement; net ~$1.9M for TAAP and MPAR programs and working capital.
- Conversion price fixed at $0.55 per share; warrants with 100% coverage (18-month and 5-year terms) at $0.55 exercise price.
- Amended Series B preferred stated value from $1,100 to $1,200 per share and issued 8,727,273 warrants.
- CEO Lynn Kirkpatrick states financing reflects continued investor confidence in the company's analgesic programs.
- Financing is part of up to $20M commitment available over 24 months from institutional investor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315226015602/0001493152-26-015602-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315226015602/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-015602

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer